Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy

NCT01615120 is registered in ClinicalTrials.gov with GTx as lead sponsor.

NCT NCT01615120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01615120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Lead sponsor
GTx
Phase
Phase 2
Overall status
Completed
Start date
August 14, 2012
Completion date
November 9, 2016
Enrollment
77 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer